

Patient Name SAMPLEREP,CTCC	Patient ID SA00054165	Age 46	Gender F	Order # SA00054165
Ordering Phys CLIENT,CLIENT				DOB 06/10/1966
Client Order # SA00054165	Account Information			Report Notes
Collected 02/26/2013 11:23	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 02/27/2013 12:59				

Test	Flag	Results	Unit	Reference Value	Perform Site*
Circulating Tumor Cells, Colorectal			REPORTED 02/27/2013 12:14		
Specimen		Whole Blood			MCR
Specimen ID		1060914			MCR
Order Date		27 Feb 2013 08:41			MCR
Reason for Referral		Assess for Circulating Tumor Cells			MCR
Method		CellSearch (TM) System			MCR
Result		Unfavorable, 5 circulating tumor cells/7.5 mL of blood.			MCR
Interpretation		The results of this test are unfavorable (> or = 3 circulating tumor cells/7.5 mL of blood). These results have been interpreted by a physician.			MCR
Previous CellSearch Specimens (up to 5):					
DATE	# CTCs	RESULT			
11/02/2012	2	Favorable			
10/02/2012	1	Favorable			
11/02/2009	0	Favorable			
11/02/2008	0	Favorable			
10/02/2008	0	Favorable			

In patients with metastatic colon cancer, unfavorable results are predictive of shorter progression-free survival (PFS).

In one prospective multicenter study, circulating tumor cells (CTCs) were enumerated in the peripheral blood of 430 patients with metastatic colorectal cancer at baseline and after starting first-, second-, or third-line therapy. CTCs were measured using an immunomagnetic separation technique. Patients were stratified into unfavorable and favorable prognostic groups based on CTC levels of three or more or less than three CTCs/7.5 mL, respectively. Patients with unfavorable compared with favorable baseline CTCs had shorter median progression-free survival (PFS; 4.5 v 7.9 months; P = .0002) and overall survival (OS; 9.4 v 18.5 months; P < .0001). Differences persisted at 1 to 2, 3 to 5, 6 to 12, and 13 to 20 weeks after therapy. Conversion of baseline unfavorable CTCs to favorable at 3 to 5 weeks was associated with significantly longer PFS and OS compared with patients with unfavorable CTCs at both time points

Performing Site Legend on Last Page of Report

Patient Name SAMPLEREP,CTCC	Collection Date and Time 02/26/2013 11:23	Report Status Final
Page 1 of 2	>> Continued on Next Page >>	

* Report times for Mayo performed tests are CST/CDT

Patient Name SAMPLEREP,CTCC	Patient ID SA00054165	Age 46	Gender F	Order # SA00054165
Ordering Phys CLIENT,CLIENT				DOB 06/10/1966
Client Order # SA00054165	Account Information			Report Notes
Collected 02/26/2013 11:23	C7028846-DLMP Rochester 3050 Superior Drive Rochester, MN 55901			
Printed 02/27/2013 12:59				

Test	Flag	Results	Unit	Reference Value	Perform Site*
		(PFS, 6.2 v 1.6 months; P = .02; OS, 11.0 v 3.7 months; P = .0002). Among non-progressing patients, favorable compared with unfavorable CTCs within 1 month of imaging was associated with longer survival (18.8 v 7.1 months; P < .0001). Baseline and follow-up CTC levels remained strong predictors of PFS and OS after adjustment for clinically significant factors (Cohen SJ et al., J Clin Oncol. 26:3213-21, 2008.)			
Reviewed By		Angela H Zieman			MCR
Release Date		27 Feb 2013 12:13			MCR

* Performing Site:

MCR	Mayo Clinic Laboratories - Rochester Main Campus 200 First St SW Rochester, MN 55905	Lab Director:
-----	---	---------------

Patient Name SAMPLEREP,CTCC	Collection Date and Time 02/26/2013 11:23	Report Status Final
Page 2 of 2		** End of Report **

* Report times for Mayo performed tests are CST/CDT